CARB-X, a Boston University-led nonprofit that funds projects that focus on antimicrobial stewardship, awarded $467,000 to GlyProVac to develop a maternal vaccine that could prevent sepsis in infants, according to a Feb. 29 news release.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
